 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
8 News |  |
- | CV8102 / CureVac
Journal, Checkpoint inhibition: Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity. (Pubmed Central) - Nov 3, 2022
P1
Therefore, i.t. CV8102 delivery is a promising approach for local cancer immunotherapy, especially in combination with CPIs. Clinical testing of CV8102 is ongoing (NCT03291002).
- CV8102 / CureVac
Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from ongoing expansion part in study 008 (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1100;
P1
Consent Written informed consent from the patient was obtained for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
- CV8102 / CureVac
Immune profiling of patients with advanced Melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies - results of a Phase I trial expansion (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1098;
P1
Conclusions Intratumoral injection of CV8102 activated several pathways of immune response detectable in peripheral blood after the first dose and showed immunological changes in the tumor microenvironment, with increased parameters of immune infiltration in a group of patients. Trial Registration NCT03291002
- || CV8102 / CureVac
P1/2 data, Clinical Trial,Phase II, Journal: Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. (Pubmed Central) - Jun 15, 2022
P1/2
The results are initial evidence for safety and immunogenicity of the vaccine. Further clinical evaluations are warranted.
- || CV8102 / CureVac
Enrollment closed, Metastases: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (clinicaltrials.gov) - Nov 4, 2021
P1, N=98, Active, not recruiting, Sponsor: CureVac AG
Further clinical evaluations are warranted. Recruiting --> Active, not recruiting
- CV8102 / CureVac
Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in Phase I clinical trial (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_433;
P1
Conclusions Intratumoral injection of CV8102 activated several cytokine/chemokine pathways in the peripheral blood and showed immunological changes in the tumor microenvironment of injected and non-injected lesions. Trial Registration NCT03291002
- CV8102 / CureVac
[VIRTUAL] Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2317;
P1
Trial Registration NCT03291002 CV8102 showed an acceptable safety profile and preliminary evidence of clinical efficacy as single agent and in combination with anti-PD-1-antibodies.
- || Review, Journal: Current status of intralesional agents in treatment of malignant melanoma. (Pubmed Central) - Jul 20, 2021
This review focuses on the current status of IT agents currently under clinical trials in melanoma. Reviewed therapies include T-VEC, T-VEC with immune checkpoint inhibitors including ipilimumab and pembrolizumab or other agents, RP1, OrienX010, Canerpaturev (C-REV, HF10), CAVATAK (coxsackievirus A21, CVA21) alone or in combination with checkpoint inhibitors, oncolytic polio/rhinovirus recombinant (PVSRIPO), MAGE-A3-expressing MG1 Maraba virus, VSV-IFNbetaTYRP1, suicide gene therapy, ONCOS-102, OBP-301 (Telomelysin), Stimulation of Interferon Genes Pathway (STING agonists) including DMXAA, MIW815 (ADU-S100) and MK-1454, PV-10, toll-like receptors (TLRs) agonists including TLR-9 agonists (SD-101, CMP-001, IMO-2125 or tilsotolimod, AST-008 or cavrotolimod, MGN1703 or lefitolimod), CV8102, NKTR-262 plus NKTR-214, LHC165, G100, intralesional interleukin-2, Daromun (L19IL2 plus L19TNF), Hiltonol (poly-ICLC), electroporation including calcium electroporation and plasmid interleukin-12 electroporation (pIL-12 EP), IT ipilimumab, INT230-6 (cisplatin and vinblastine with an amphiphilic penetration enhancer), TTI-621 (SIRPαFc), CD-40 agonistic antibodies (ABBV-927 and APX005M), antimicrobial peptide LL37 and other miscellaneous agents.
- Hepavac (IMA970A) / Immatics, CureVac
[VIRTUAL] Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients () - May 30, 2021 - Abstract #EACR2021EACR_2243;
P1/2
Immunogenicity data show immune response against at least 1 vaccine class I TAA and 1 vaccine class II TAA in about 70% and 50% of the vaccines, respectively. Conclusion The results of the HEPAVAC-101 clinical trial provide the grounding evidences for futher evaluation in subsequent steps.
- Hepavac (IMA970A) / Immatics, CureVac
[VIRTUAL] Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients () - May 30, 2021 - Abstract #EACR2021EACR_2242;
P1/2
Immunogenicity data show immune response against at least 1 vaccine class I TAA and 1 vaccine class II TAA in about 70% and 50% of the vaccines, respectively. Conclusion The results of the HEPAVAC-101 clinical trial provide the grounding evidences for futher evaluation in subsequent steps.
- Hepavac (IMA970A) / Immatics, CureVac
[VIRTUAL] Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients () - May 30, 2021 - Abstract #EACR2021EACR_2241;
P1/2
Immunogenicity data show immune response against at least 1 vaccine class I TAA and 1 vaccine class II TAA in about 70% and 50% of the vaccines, respectively. Conclusion The results of the HEPAVAC-101 clinical trial provide the grounding evidences for futher evaluation in subsequent steps.
- Hepavac (IMA970A) / Immatics, CureVac
[VIRTUAL] Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients () - May 30, 2021 - Abstract #EACR2021EACR_2240;
P1/2
Immunogenicity data show immune response against at least 1 vaccine class I TAA and 1 vaccine class II TAA in about 70% and 50% of the vaccines, respectively. Conclusion The results of the HEPAVAC-101 clinical trial provide the grounding evidences for futher evaluation in subsequent steps.
- Hepavac (IMA970A) / Immatics, CureVac
[VIRTUAL] Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients. (eTalks Room) - May 11, 2021 - Abstract #CIMT2021CIMT_19;
P1/2
It is a highly innovative, novel approach based on a multi-peptide vaccine (IMA970A) combined with the TLR7/8/RIG I agonist CV8102 as an adjuvant. The results of the HEPAVAC-101 clinical trial provide the grounding evidences for futher evaluation in subsequent steps.
- Hepavac (IMA970A) / Immatics, CureVac
[VIRTUAL] Results of the therapetuic cancer vaccine HepaVac-101 clinical trial in HCC patients () - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_729;
P1/2
It is a highly innovative, novel approach based on a multi-peptide vaccine (IMA970A) combined with the TLR7/8/RIG I agonist CV8102 as an adjuvant. The HEPAVAC-101 clinical trial is safe and elicits immune response in HCC patients.
- || CV8102 / CureVac
Enrollment change, Metastases: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (clinicaltrials.gov) - Jan 22, 2021
P1, N=98, Recruiting, Sponsor: CureVac AG
The HEPAVAC-101 clinical trial is safe and elicits immune response in HCC patients. N=233 --> 98
- ||| CV8102 / CuraVac
$CVAC CV8102 (TLR7/8 & Rig1 agonist ssRNA) looks better than $MRK, but mind the tox #SITC20 (Twitter) - Nov 13, 2020
- CV8102 / CuraVac
[VIRTUAL] A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2106;
P1
Updated safety and efficacy results will be presented. Conclusions CV8102 showed an acceptable tolerability and preliminary evidence of clinical efficacy as single agent and in combination with anti-PD-1- antibodies.
- CV8102 / CuraVac
[VIRTUAL] A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_1963;
P1
Updated safety and efficacy results will be presented. Conclusions CV8102 showed an acceptable tolerability and preliminary evidence of clinical efficacy as single agent and in combination with anti-PD-1- antibodies.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (Channel 1) - Aug 22, 2020 - Abstract #EASLILCI2020EASL-ILC-I-2139;
P1/2
The HEPAVAC-101 clinical trial is the achievement of the HEPAVAC Consortium supported by the European Commission’s 7th framework program with contract No. 602893 (www.hepavac.eu).
- || CV8102 / CuraVac
Clinical, P1 data, Journal: RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial. (Pubmed Central) - Aug 13, 2020
EudraCT No. 2013-004514-18.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1235;
P1/2
The HEPAVAC-101 clinical trial is the achievement of the HEPAVAC Consortium supported by the European Commission’s 7th framework program with contract No. 602893 (www.hepavac.eu).
- cyclophosphamide intravenous / Generic mfg.
Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_590;
P1/2
The HEPAVAC-101 clinical trial is the achievement of the HEPAVAC Consortium supported by the European Commission’s 7th framework program with contract No. 602893 (www.hepavac.eu).
- CV8102 / CuraVac
[VIRTUAL] A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors. (Poster Board 160) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1371;
P1
Updated results on safety, efficacy and serum biomarkers will be presented. Research Funding: CureVac AG
- || CV8102 / CureVac
Trial completion date, Trial primary completion date, Metastases: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (clinicaltrials.gov) - Mar 19, 2020
P1, N=209, Recruiting, Sponsor: CureVac AG
Research Funding: CureVac AG Trial completion date: Jul 2021 --> Feb 2023 | Trial primary completion date: Mar 2021 --> Oct 2022
- || Hepavac (IMA970A) / Immatics, CureVac, CV8102 / CureVac
Trial completion: IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Feb 5, 2020
P1/2, N=22, Completed, Sponsor: National Cancer Institute, Naples
Trial completion date: Jul 2021 --> Feb 2023 | Trial primary completion date: Mar 2021 --> Oct 2022 Active, not recruiting --> Completed
- CV8102 / CuraVac
Intratumoral application of the RNA-based TLR7/-8 and RIG-I agonist CV8102 leads to a pro-inflammatory tumor microenvironment and durable anti-tumor Effects () - Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_235;
Preliminary data show that intratumoral CV8102 appears to be well tolerated. Importantly, evidence of clinical single agent activity with shrinkage of injected and non-injected lesions has been observed.
- CV8102 / CuraVac
Intratumoral application of the RNA-based TLR-7/-8 and RIG-I agonist CV8102 promotes a pro-inflammatory tumor microenvironment and causes a durable anti-tumor response (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_999;
By modulating the tumor microenvironment CV8102 induces potent anti-tumoral immune responses and improves CPI efficacy in mice. An ongoing phase I trial is investigating intratumoral CV8102 either as a monotherapy or in combination with systemic anti-PD-1 treatment in various tumor entities (see abstract by Eigentler et al.).
- CV8102 / CuraVac
A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (Prince George's Exhibition Hall C) - Oct 2, 2019 - Abstract #SITC2019SITC_321;
IT CV8102 single-agent and in combination with systemic anti-PD-1 antibodies appears well tolerated to date and showed evidence of single agent activity with shrinkage of injected and non-injected lesions. Updated results will be presented.
- CV8102 / CuraVac
A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1531;
P1
Legal entity responsible for the study: CureVac AG. Funding: CureVac AG.
- | Hepavac (IMA970A) / Immatics, CureVac, CV8102 / CureVac
Enrollment closed, Enrollment change: IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Aug 20, 2019
P1/2, N=22, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Funding: CureVac AG. Recruiting --> Active, not recruiting | N=40 --> 22
- || CV8102 / CureVac
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (clinicaltrials.gov) - Apr 10, 2019
P1, N=209, Recruiting, Sponsor: CureVac AG
Recruiting --> Active, not recruiting | N=40 --> 22 N=146 --> 209 | Trial completion date: Dec 2019 --> Jul 2021 | Trial primary completion date: Jul 2019 --> Mar 2021
- | Hepavac (IMA970A) / Immatics, CureVac, CV8102 / CureVac
Trial completion date, Trial primary completion date: IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Dec 21, 2018
P1/2, N=40, Recruiting, Sponsor: National Cancer Institute, Naples
N=146 --> 209 | Trial completion date: Dec 2019 --> Jul 2021 | Trial primary completion date: Jul 2019 --> Mar 2021 Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
- | CV8102 / CureVac
Enrollment change, Metastases: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (clinicaltrials.gov) - Aug 29, 2018
P1, N=146, Recruiting, Sponsor: CureVac AG
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020 N=104 --> 146
- ||| CV8102 / CureVac
Trial completion, Combination therapy: Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Jun 6, 2018
P1, N=72, Completed, Sponsor: CureVac AG
N=104 --> 146 Active, not recruiting --> Completed
- ||| CV8102 / CureVac
Enrollment open, Metastases: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (clinicaltrials.gov) - Sep 28, 2017
P1, N=104, Recruiting, Sponsor: CureVac AG
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| CV8102 / CureVac
New P1 trial, Metastases: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (clinicaltrials.gov) - Sep 25, 2017
P1, N=104, Not yet recruiting, Sponsor: CureVac AG
- | Hepavac (IMA970A) / Immatics, CureVac, CV8102 / CureVac
Enrollment open, IO biomarker: IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Sep 21, 2017
P1/2, N=40, Recruiting, Sponsor: National Cancer Institute, Naples
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Hepavac (IMA970A) / Immatics, CureVac, CV8102 / CureVac
New P1/2 trial, IO biomarker: IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Jun 29, 2017
P1/2, N=40, Not yet recruiting, Sponsor: National Cancer Institute, Naples
- || CV8102 / CureVac
Trial primary completion date, Combination therapy: Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Jul 29, 2016
P1, N=72, Active, not recruiting, Sponsor: CureVac AG
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Aug 2016
- CV8102 / CureVac
Enrollment closed, Combination therapy: Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Dec 4, 2015
P1, N=72, Active, not recruiting, Sponsor: CureVac AG
Trial primary completion date: Feb 2016 --> Aug 2016 Recruiting --> Active, not recruiting
- ||| CV8102 / CureVac
Enrollment open, Combination therapy: Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Sep 15, 2014
P1, N=72, Recruiting, Sponsor: CureVac GmbH
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| CV8102 / CureVac
New P1 trial, Combination therapy: Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Sep 12, 2014
P1, N=72, Not yet recruiting, Sponsor: CureVac GmbH